Effects of EGFR tyrosine kinase inhibitor erlotinib in prostate cancer cells in vitro

BACKGROUND Erlotinib is a small‐molecule tyrosine kinase inhibitor targeted EGFR, known to be overexpressed in a variety of cancers, including prostate cancer. Clinical trials showed insignificant clinical benefit in patients with castration resistant prostate cancer both when EGFR inhibitors were a...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	The Prostate 2009-10, Vol.69 (14), p.1529-1537
Hauptverfasser:	Festuccia, Claudio, Gravina, Giovanni Luca, Biordi, Leda, D'Ascenzo, Sandra, Dolo, Vincenza, Ficorella, Corrado, Ricevuto, Enrico, Tombolini, Vincenzo
Format:	Artikel
Sprache:	eng
Schlagworte:	Apoptosis - drug effects Biological and medical sciences Cell Cycle Proteins - metabolism Cell Division - drug effects Cell Line, Tumor EGFR erlotinib Erlotinib Hydrochloride Gene Expression Regulation, Neoplastic Gynecology. Andrology. Obstetrics Humans In Vitro Techniques Male Male genital diseases Medical sciences Nephrology. Urinary tract diseases prostate cancer Prostatic Neoplasms - drug therapy Prostatic Neoplasms - pathology Protein Kinase Inhibitors - pharmacology PTEN Phosphohydrolase - genetics PTEN Phosphohydrolase - metabolism Quinazolines - pharmacology Receptor, Epidermal Growth Factor - antagonists & inhibitors Receptor, Epidermal Growth Factor - metabolism Receptors, Androgen - genetics Receptors, Androgen - metabolism RNA, Small Interfering Signal Transduction - drug effects Tumors Tumors of the urinary system Urinary tract. Prostate gland
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Schreiben Sie den ersten Kommentar!